Contact
searchSearch
HMP Global

Lung Cancer Learning Library

Narjust Florez, MD, and Stephanie McDonald, MSN, FNP-BC, AOCNP
Videos
Highlight from the 2026 World Conference on Lung Cancer: Part 1
11/11/2026
Narjust Florez, MD; Stephanie McDonald, MSN
Narjust Florez, MD, thoracic medical oncologist at Dana-Farber Cancer Institute, assistant professor of medicine at Harvard Medical School, and co-director of the Young Lung Cancer Program at Dana-Farber, and Stephanie McDonald, MSN, FNP-BC,...
Narjust Florez, MD, thoracic medical oncologist at Dana-Farber Cancer Institute, assistant professor of medicine at Harvard Medical School, and co-director of the Young Lung Cancer Program at Dana-Farber, and Stephanie McDonald, MSN, FNP-BC,...
Narjust Florez, MD, thoracic...
11/11/2026
Oncology Learning Network APP Institute
News
Timely NSCLC Biomarker Testing: The Oncology APP’s Role
10/16/2026
Kirra Fedyszyn
Key takeaways Approximately one-third of survey respondents reported that non-small cell lung cancer (NSCLC) biomarker results were unavailable before initial treatment decisions. Focus group participants identified clearly defined...
Key takeaways Approximately one-third of survey respondents reported that non-small cell lung cancer (NSCLC) biomarker results were unavailable before initial treatment decisions. Focus group participants identified clearly defined...
Key...
10/16/2026
Oncology Learning Network APP Institute
Narjust Florez, MD, and Stephanie McDonald, MSN, FNP-BC, AOCNP
Videos
Lung Cancer Insights from ASCO 2026: What Every APP Needs to Know
09/10/2026
Narjust Florez, MD; Stephanie McDonald, MSN
Narjust Florez, MD, and Stephanie McDonald, MSN, FNP-BC, AOCNP, discuss key lung cancer findings from the 2026 ASCO Annual Meeting and their implications for oncology APPs. They review long-term CROWN data supporting first-line lorlatinib in...
Narjust Florez, MD, and Stephanie McDonald, MSN, FNP-BC, AOCNP, discuss key lung cancer findings from the 2026 ASCO Annual Meeting and their implications for oncology APPs. They review long-term CROWN data supporting first-line lorlatinib in...
Narjust Florez, MD, and...
09/10/2026
Oncology Learning Network APP Institute
David Spigel, MD, Sarah Cannon Research Institute
Videos
Molecular Assay May Predict Patients With Non-Small Cell Lung Cancer to Benefit From Adjuvant Therapy
06/16/2025
David Spigel, MD
David Spigel, MD, discusses the results of the AIM-HIGH trial to evaluating the predictive efficacy of a 14-gene expression profile in identifying stage Ia to IIa patients with non-squamous NSCLC who benefit from adjuvant therapy.
David Spigel, MD, discusses the results of the AIM-HIGH trial to evaluating the predictive efficacy of a 14-gene expression profile in identifying stage Ia to IIa patients with non-squamous NSCLC who benefit from adjuvant therapy.
David Spigel, MD, discusses the...
06/16/2025
Oncology Learning Network APP Institute
Patrick Forde, MBBCh
Videos
Neoadjuvant Nivolumab Plus Chemotherapy Shows Long-Term Survival Benefit Among Patients With Resectable Non-Small Cell Lung Cancer
06/05/2025
Patrick Forde, MD
Patrick Forde, MBBCh, shares insights on the long-term overall survival benefit demonstrated by neoadjuvant nivolumab plus chemotherapy among patients with resectable non-small cell lung cancer, as seen in the CheckMate 816 trial.
Patrick Forde, MBBCh, shares insights on the long-term overall survival benefit demonstrated by neoadjuvant nivolumab plus chemotherapy among patients with resectable non-small cell lung cancer, as seen in the CheckMate 816 trial.
Patrick Forde, MBBCh, shares...
06/05/2025
Oncology Learning Network APP Institute
Andria Caton, MSN, OCN, CHPN
Conference Coverage
Impact of Lung Cancer and Tobacco Use Prevention Program Among Students
04/24/2025
Insights from an evidence-based educational program to prevent lung cancer caused by smoking and vaping were presented at the 2025 ONS Congress by Andria Caton, MSN, OCN, CHPN.
Insights from an evidence-based educational program to prevent lung cancer caused by smoking and vaping were presented at the 2025 ONS Congress by Andria Caton, MSN, OCN, CHPN.
Insights from an evidence-based...
04/24/2025
Oncology Learning Network APP Institute
Benjamin Besse, MD, PhD
Videos
First-Line Amivantamab Plus Lazertinib Demonstrates Promise in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
10/28/2024
Benjamin Besse, MD, PhD, discusses early analysis results from the MARIPOSA study which demonstrated that amivantamab plus lazertinib has promising antitumor activity in patients with advanced EGFR-mutated NSCLC.
Benjamin Besse, MD, PhD, discusses early analysis results from the MARIPOSA study which demonstrated that amivantamab plus lazertinib has promising antitumor activity in patients with advanced EGFR-mutated NSCLC.
Benjamin Besse, MD, PhD,...
10/28/2024
Oncology Learning Network APP Institute
Oncology Learning Network APP Institute logo

The APP Institute is a new offering from the Oncology Learning Network that provides microburst education to oncology advanced practitioners. The platform offers year-round digital non-accredited learning modules through animated short videos, multimedia interviews with key opinion leaders, interactive content to test your knowledge, and more!

 

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use